



ASX ANNOUNCEMENT

29 March 2021

Respiratory Physician led telehealth and remote patient management programme launching in Australia that will also be the basis of the model for the US reimbursement market.

RespiRI Limited (ASX:RSH) (“RespiRI” or the “Company”), an eHealth SaaS Company supporting respiratory health management, is pleased to announce the commencement of a telehealth and remote management programme trial with a Respiratory Physician to support asthma management beyond the clinic.

RespiRI and Dr Kevin Chan (a leading Respiratory Physician working at Campbelltown Hospital & Sydney Adventist Hospital, Wahroonga) will lead a remote monitoring program that brings together the treating respiratory specialist, primary care provider, wheezo™ and RespiRI’s Connected Care Nurse team, to provide a world-class ambulatory care service for patients with moderate to severe persistent asthma. Patients will be charged a premium monthly Product as a Service (PaaS) fee to access the programme. It is planned that this programme will be scaled to other Respiratory physicians and also create a potential corporate health respiratory offering for employers/companies.

Dr Chan, said, “I have many patients who come and see me, describing their wheeze and other respiratory symptoms that happened weeks prior, which does not paint an accurate or complete picture of the patient’s respiratory condition. Through remote digital monitoring and Connected Care consults, I expect to be in a much better position to understand the patient’s progress on a day-to-day basis. This is particularly important for patients with poor asthma control.”

Further, following on from the recently announced FDA approval of wheezo, the programme will also form the basis for the patient model intended for the USA reimbursement market, taking advantage of the Remote Patient Monitoring Current Procedural Terminology (CPT) Codes where RespiRI &/or partners charge a monthly Product as a Service fee (PaaS) of between USD30-USD40 to physicians for each patient they enrol.

Initially trialled with Dr Chan, who says that “asthma is one of the most common conditions he treats at his practice”, patients will pay an ongoing Product as a Service (PaaS) fee and their clinical information will be uploaded regularly for review. He will have real time access to patient data via the portal and RespiRI’s Connected Care Nurse team will consult with the patients monthly, giving the patient insights into their data and whilst also securing patient feedback.

“This program represents a fantastic opportunity to trial wheezo with PaaS fee-paying patients in a clinical setting and will allow us to use real-world data to establish a scalable patient pathway that aims to improve the lives of asthma sufferers across Australia and very importantly provide us with the patient model and programme for the US prescription/reimbursement market” said RespiRI CEO, Marjan Mikel.

The programme is to be launched in April 2021.

For further information about wheezo, follow the online link <https://wheezo.com>

- ENDS -

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

™ wheezo is a trademark of Respiri Limited.

This ASX announcement dated 29 March 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo, Respiri's innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

Respiri's mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited's operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.